Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
AssigneeAmgen Inc.
InventorsKenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
Life of this patent
Estimating the term…
Abstract
This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of these antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
Claims8
An isolated monoclonal antibody that specifically binds to an epitope on human nerve growth factor (NGF), said isolated monoclonal antibody comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1 (SEQ ID NO:
- 22), CDR2 (SEQ ID NO:
- 18), and CDR3 (SEQ ID NO:
- 14) of SEQ ID NO:
- 10, and a light chain variable region, wherein the light chain variable region comprises CDR1 (SEQ ID NO:
- 24), CDR2 (SEQ ID NO:
- 20), and CDR3 (SEQ ID NO:
- 16) of SEQ ID 12.
Dependencies are inferred from the claim text.